Advertisement

Safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience

  • Dan Călugăru
  • Mihai CălugăruEmail author
Letter to the Editor
  • 87 Downloads

Dear Editor:

We would like to address several challenges that have arisen from the study by Blanc et al. [1] which can be specifically summarized below.

The study was retrospectively conducted with a small sample size of retinal vein occlusions (RVO) divided into two groups with unbalanced numbers of patients, namely, group 1 including patients who received dexamethasone (DEX) implant injections only (Ozurdex, Allergan, Inc., CA, USA) and group 2 with patients who received DEX implants first and then were switched to anti-vascular endothelial growth factor (VEGF) agents.

There was a selection bias attributable to inclusion in the study and pooled analysis of patients with two forms of RVOs (ischemic and nonischemic occlusions) having totally different pathogenesis, clinical features, prognoses, and management. Likewise, the inclusion in the study of two types of RVOs (branch and central retinal vein) was inappropriate because they have different etiology, pathogenesis, and prognosis [2...

Notes

Authors’ contribution

Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Blanc J, Deschasse C, Kodjikian L, Dot C, Bron AM, Creuzot-Garcher C (2018) Safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience. Graefes Arch Clin Exp Ophthalmol.  https://doi.org/10.1007/s00417-018-4016-7. Published online: May 31, 2018CrossRefGoogle Scholar
  2. 2.
    Călugăru D, Călugăru M (2018) Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol 256:1209–1210CrossRefGoogle Scholar
  3. 3.
    Călugăru D, Călugăru M (2017) Baseline choroidal thickness as a predictor for treatment outcomes in central retinal vein occlusion. Am J Ophthalmol 176:257–258CrossRefGoogle Scholar
  4. 4.
    Călugăru D, Călugăru M (2017) Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with macular edema secondary to vein occlusion. Am J Ophthalmol 184:190–191CrossRefGoogle Scholar
  5. 5.
    Călugăru D, Călugăru M (2017) Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal. Eur J Ophthalmol 27:e190–e191CrossRefGoogle Scholar
  6. 6.
    Călugăru D, Călugăru M (2015) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion. The Rubeosis anti-VEGF (rave) trial. Retina 35:e59–e61CrossRefGoogle Scholar
  7. 7.
    Călugăru D, Călugăru M (2017) Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion. Can J Ophthalmol 52:137CrossRefGoogle Scholar
  8. 8.
    Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul PharmacolTher 31:78–86CrossRefGoogle Scholar
  9. 9.
    Călugăru D, Călugăru M (2017) Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion. Int J Ophthalmol 10:1481–1482PubMedPubMedCentralGoogle Scholar
  10. 10.
    Călugăru D, Călugăru M (2017) Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. Eye 31:1112–1113CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-Napoca/RomaniaCluj-NapocaRomania

Personalised recommendations